With Roche's R&D arm stepping back into antibiotics development, the pharma giant has struck a $425 million deal--with $190 million upfront--to buy a U.S. diagnostics outfit that's been developing some rapid-fire tech for matching the right antibiotic with the right bug.
There's just over two weeks left until Mylan's shareholders vote on its proposed hostile takeover of Perrigo, and the Irish target is using the time to meet with shareholders of both companies. Right now, its leaders feel "good about where they stand," according to Bernstein analyst Ronny Gal--but there are some question marks hanging over them, too.
Australian vaccines maker CSL has plenty of wherewithal to make some deals, CEO Paul Perreault says, but he's wary of the prices paid by other drugmakers. Big Pharma's penchant for biotech deals has created "a bit of a bubble," in Perreault's view.
Last week, Baxalta rejected a $30 billion buyout bid from Shire, pointing to its youth, its standalone prospects and a portfolio that just wouldn't jibe with the Irish pharma's. On Monday, its CEO hammered those points home once again for investors--and stressed that Shire's proposal, as it stands, is "wholly inadequate."
Baxalta CEO Ludwig Hantson, barely a month into his tenure, is already fending off an unwelcome takeover attempt, telling shareholders Monday that Shire's roughly $30 billion offer is woefully inadequate and that he and his board have no intention of taking it.
Mallinckrodt has made its second buy of the year--and the company believes it's the perfect match for its first purchase.
Sorrento Therapeutics, closely allied with Patrick Soon-Shiong's fast-growing oncology drug empire, has bagged two private biotech companies, adding some CAR-T therapies to the mix.
U.K.-based veterinary drug maker Dechra Pharmaceuticals is buying a controlling share of Genera for $56.4 million in a move to expand its presence in the growing demand for poultry vaccines.
Horizon Pharma, which is trying to buy Depomed, today reported a small profit for Q2. It said sales soared 161%, hitting $172.8 million as revenues from newly acquired products kicked in.
Horizon Pharma has told target Depomed that it's prepared to hike its $2 billion offer for the company and throw in a cash component of up to 25%, according to Depomed chief Jim Schoeneck. And he wants to know where that sweetened offer is.